• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Intercept Pharmaceuticals Inc.

    10/11/22 8:29:45 PM ET
    $ICPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ICPT alert in real time by email
    SC 13G 1 i100722a.htm SCHEDULE 13G
    240.13d-102 Schedule 13G - Information to be included in statements filed
    pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
    filed pursuant to 240.13d-2.
    Securities and Exchange Commission, Washington, D.C. 20549
    Schedule 13G
    Under the Securities Exchange Act of 1934
    (Amendment No._)*
    (Name of Issuer)
    Intercept Pharmaceuticals, Inc.
    (Title of Class of Securities)
    Common Stock, Par Value $0.001 Per Share

    (CUSIP Number)

    45845P108

    (Date of Event Which Requires Filing of this Statement)

    October 3, 2022

    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:
    [  ] Rule 13d-1(b)
    [ x ] Rule 13d-1(c)
    [  ] Rule 13d-1(d)
    *The remainder of this cover page shall be filled out for a reporting person's
    initial filing on this form with respect to the subject class of securities, and
    for any subsequent amendment containing information which would alter the
    disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be
    deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
    Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
    Act but shall be subject to all other provisions of the Act (however, see
    the Notes).



    CUSIP No. 45845P108
    (1) Names of reporting persons    Point72 Asset Management, L.P.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              2,019,983 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       2,019,983 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    2,019,983 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 4.9% ** (see Item 4)
     
    (12) Type of reporting person (see instructions) PN
     



    CUSIP No. 45845P108
    (1) Names of reporting persons    Point72 Capital Advisors, Inc.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              2,019,983 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       2,019,983 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    2,019,983 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 4.9% ** (see Item 4)
     
    (12) Type of reporting person (see instructions) CO
     



    CUSIP No. 45845P108
    (1) Names of reporting persons    Cubist Systematic Strategies, LLC
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              327,425 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       327,425 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    327,425 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0.8% ** (see Item 4)
     
    (12) Type of reporting person (see instructions) OO
     



    CUSIP No. 45845P108
    (1) Names of reporting persons    Point72 Middle East FZE
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United Arab Emirates
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              13,461 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       13,461 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    13,461 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) <0.1% ** (see Item 4)
     
    (12) Type of reporting person (see instructions) OO
     



    CUSIP No. 45845P108
    (1) Names of reporting persons    Steven A. Cohen
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United States
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              2,360,869 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       2,360,869 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    2,360,869 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 5.7% ** (see Item 4)
     
    (12) Type of reporting person (see instructions) IN
     



    Item 1(a) Name of issuer:
    Intercept Pharmaceuticals, Inc.
    Item 1(b) Address of issuer's principal executive offices:
    305 Madison Avenue, Morristown, NJ 07960
    2(a) Name of person filing:
    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset
    Management”) with respect to shares of common stock, par value $0.001 per share
    (“Shares”), of the Issuer held by certain investment funds it manages; (ii)
    Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect
    to Shares held by certain investment funds managed by Point72 Asset
    Management; (iii) Cubist Systematic Strategies, LLC (“Cubist Systematic
    Strategies”) with respect to Shares held by certain investment funds it
    manages; (iv) Point72 Middle East FZE (“Point72 Middle East”) with respect to
    Shares held by certain investment funds it manages; and (v) Steven A. Cohen
    (“Mr. Cohen”) with respect to Shares beneficially owned by Point72 Asset
    Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and
    Point72 Middle East.

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic
    Strategies, Point72 Middle East, and Mr. Cohen have entered into a Joint Filing
    Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1,
    pursuant to which they have agreed to file this Schedule 13G jointly in
    accordance with the provisions of Rule 13d-1(k) of the Act.
    2(b) Address or principal business office or, if none, residence:
    The address of the principal business office of (i) Point72 Asset Management,
    Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road,
    Stamford, CT 06902; (ii) Cubist Systematic Strategies is 55 Hudson Yards,
    New York, NY 10001; and (iii) Point72 Middle East is EO3, 04, Sheikh Rashid
    Tower, Dubai World Trade Centre, Dubai, United Arab Emirates.
    2(c) Citizenship:
    Point72 Asset Management is a Delaware limited partnership. Point72 Capital
    Advisors Inc. is a Delaware corporation. Cubist Systematic Strategies is a Delaware
    limited liability company. Point72 Middle East is a limited liability free zone
    establishment. Mr. Cohen is a United States citizen.
    2(d) Title of class of securities:
    Common Stock, Par Value $0.001 Per Share
    2(e) CUSIP Number:
    45845P108

    Item 3.

    Not applicable

    Item 4. Ownership

    As of the close of business on October 10, 2022:

    1. Point72 Asset Management, L.P.
    (a) Amount beneficially owned: 2,019,983
    (b) Percent of class: 4.9% **
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 2,019,983 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 2,019,983

    2. Point72 Capital Advisors, Inc.
    (a) Amount beneficially owned: 2,019,983
    (b) Percent of class: 4.9% **
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 2,019,983 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 2,019,983

    3. Cubist Systematic Strategies, LLC
    (a) Amount beneficially owned: 327,425
    (b) Percent of class: 0.8% **
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 327,425 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 327,425

    4. Point72 Middle East FZE
    (a) Amount beneficially owned: 13,461
    (b) Percent of class: <0.1% **
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 13,461 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 13,461

    5. Steven A. Cohen
    (a) Amount beneficially owned: 2,360,869
    (b) Percent of class: 5.7% **
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 2,360,869 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 2,360,869

    **
    The percentages set forth herein are calculated based upon 41,371,130
    Shares outstanding, which is the sum of (i) the 39,400,000 Shares
    outstanding following the completion of the transactions disclosed in
    the Issuer’s Current Report on Form 8-K filed with the Securities and
    Exchange Commission (the “SEC”) on August 26, 2022, as disclosed
    in Exhibit 99.1 to the Issuer’s Current Report on Form 8-K filed with
    the SEC on August 19, 2022, (ii) the 1,653,130 Shares issued by the
    Issuer on September 6, 2022, as disclosed in the Issuer’s Current Report
    on Form 8-K filed with the SEC on September 6, 2022, and (iii) the
    318,000 Shares issued by the Issuer on September 8, 2022, as disclosed
    in the Issuer’s Current Report on Form 8-K filed with the SEC on September 8, 2022.

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic
    Strategies, Point72 Middle East, and Mr. Cohen own directly no Shares. Pursuant
    to an investment management agreement, Point72 Asset Management maintains
    investment and voting power with respect to the securities held by certain
    investment funds it manages. Point72 Capital Advisors Inc. is the general
    partner of Point72 Asset Management. Pursuant to an investment management
    agreement, Cubist Systematic Strategies maintains investment and voting power
    with respect to the securities held by certain investment funds it manages.
    Pursuant to an investment management agreement, Point72 Middle East maintains
    investment and voting power with respect to the securities held by certain
    investment funds it manages. Mr. Cohen controls each of Point72 Asset
    Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and
    Point72 Middle East. By reason of the provisions of Rule 13d-3 of the Securities
    Exchange Act of 1934, as amended, each of (i) Point72 Asset Management,
    Point72 Capital Advisors Inc. and Mr. Cohen may be deemed to beneficially own
    2,019,983 Shares (constituting approximately 4.9% ** of the Shares outstanding),
    (ii) Cubist Systematic Strategies and Mr. Cohen may be deemed to beneficially
    own 327,425 Shares (constituting approximately 0.8% ** of the Shares outstanding) and (iii)
    Point72 Middle East and Mr. Cohen may be deemed to beneficially own 13,461 Shares
    (constituting <0.1% ** of the Shares outstanding). Each of Point72 Asset
    Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies,
    Point72 Middle East, and Mr. Cohen disclaims beneficial ownership of any of the
    securities covered by this statement.

    Item 5.  Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof
    the reporting person has ceased to be the beneficial owner of more than
    5 percent of the class of securities, check the following [].

    Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable

    Item 7.  Identification and Classification of the Subsidiary Which Acquired
    the Security Being Reporting on by the Parent Holding Company or Control
    Person.
    Not applicable
    Item 8. Identification and Classification of Members of the Group

    Not applicable

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities
    referred to above were not acquired and are not held for the purpose of or with the
    effect of changing or influencing the control of the issuer of the securities and were
    not acquired and are not held in connection with or as a participant in any transaction
    having that purpose or effect, other than activities solely in connection with a
    nomination under§ 240.14a-11.


    Signature.  After reasonable inquiry and to the best of my knowledge and belief,
    I certify that the information set forth in this statement is true, complete
    and correct.

    Dated: October 11, 2022

    POINT72 ASSET MANAGEMENT, L.P.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    POINT72 CAPITAL ADVISORS, INC.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    CUBIST SYSTEMATIC STRATEGIES, LLC
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    POINT72 MIDDLE EAST FZE
    By: /s/ Rafael Lopez Espinosa
    Name: Rafael Lopez Espinosa
    Title: Authorized Person


    STEVEN A. COHEN
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    Get the next $ICPT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ICPT

    DatePrice TargetRatingAnalyst
    7/13/2023$8.00 → $19.00Sell → Buy
    H.C. Wainwright
    6/29/2023$12.00 → $18.00Hold → Buy
    Canaccord Genuity
    5/23/2023Buy → Hold
    Needham
    5/22/2023$8.00Neutral → Sell
    H.C. Wainwright
    5/17/2023Outperform → Mkt Perform
    Raymond James
    3/8/2022$31.00 → $29.00Hold
    Canaccord Genuity
    3/3/2022$22.00 → $16.00Sector Perform
    RBC Capital
    3/3/2022$30.00 → $25.00Buy
    Needham
    More analyst ratings

    $ICPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Intercept Pharma upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Intercept Pharma from Sell to Buy and set a new price target of $19.00 from $8.00 previously

      7/13/23 9:10:56 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intercept Pharma upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded Intercept Pharma from Hold to Buy and set a new price target of $18.00 from $12.00 previously

      6/29/23 7:24:17 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intercept Pharma downgraded by Needham

      Needham downgraded Intercept Pharma from Buy to Hold

      5/23/23 7:40:07 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ICPT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 Conference

      MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abstracts on primary biliary cholangitis (PBC) will be presented at Digestive Disease Week® (DDW) 2024. The conference will be held from May 18-21 in Washington, D.C. "We are pleased to participate in this year's DDW and share our latest findings, including new data from our Phase 2 trial evaluating a fixed-dose combination of obeticholic acid and bezafibrate in patients with PBC," said Sangeeta Sawh

      5/9/24 8:00:00 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC

      sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBCPrecedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registriesFDA has assigned a PDUFA target action date of October 15, 2024 MORRISTOWN, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supple

      2/29/24 8:30:00 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.

      BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. ("Alfasigma") and Intercept Pharmaceuticals, Inc. ("Intercept") announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc. Following the completion of Alfasigma's successful tender offer to purchase all outstanding shares of common stock of Intercept for USD 19.00 per share, net to the seller thereof in cash, without interest, less any applicable withholding of taxes, Alfasigma acquired all remaining shares of common stock of Intercept through a merger pursuant to Section 251(h) of the General Corporation Law of the St

      11/8/23 9:13:49 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ICPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

      Submission status for INTERCEPT PHARMS INC's drug OCALIVA (SUPPL-8) with active ingredient OBETICHOLIC ACID has changed to 'Approval' on 02/24/2022. Application Category: NDA, Application Number: 207999, Application Classification: Labeling

      2/25/22 4:36:46 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

      Submission status for INTERCEPT PHARMS INC's drug OCALIVA (SUPPL-7) with active ingredient OBETICHOLIC ACID has changed to 'Approval' on 05/26/2021. Application Category: NDA, Application Number: 207999, Application Classification: Labeling

      5/27/21 5:23:24 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ICPT
    Leadership Updates

    Live Leadership Updates

    See more
    • Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

      -Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in

      10/23/23 8:00:00 AM ET
      $CSTL
      $EQ
      $ICPT
      Medical Specialities
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Intercept Appoints M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer

      NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer. “Dr. Berrey brings a wealth of leadership experience in drug development and executive management to Intercept, and I am very pleased to welcome her to the team,” said Jerry Durso, President and Chief Executive Officer of Intercept. “She joins us at a pivotal time for the company as we continue to drive our foundational PB

      6/9/21 8:00:00 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intercept Appoints Dagmar Rosa-Bjorkeson to Its Board of Directors

      NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Dagmar Rosa-Bjorkeson to its Board of Directors as of April 1, 2021. Ms. Rosa-Bjorkeson has more than 25 years of global experience in the pharmaceutical industry, including executive leadership positions in corporate and product strategy, market development and operational execution. She is currently the Chief Operating Officer of Mesoblast Limited. Ms. Rosa-Bjorkeson has led multiple successful product launches, inclu

      2/23/21 8:00:00 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ICPT
    Financials

    Live finance-specific insights

    See more
    • Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023

      MORRISTOWN, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, will announce its second quarter 2023 financial results on Wednesday, August 2, 2023. The announcement will be followed by a conference call and audio webcast at 8:30 a.m. ET. Participants can access the conference call live via webcast which will be available on the investor page of the company's website at http://ir.interceptpharma.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the

      7/26/23 8:00:00 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH

      Company to discontinue all NASH-related investment and restructure the Company's operations to strengthen its focus on rare and serious liver diseasesCompany anticipates achieving profitability in 2024 as a result of planned actionsConference call scheduled for Friday, June 23, 2023, at 8:30 a.m. ET MORRISTOWN, N.J., June 22, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response to the Company's New Drug Applicat

      6/22/23 5:45:00 PM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH

      12 of 16 voting-eligible advisors vote "no" (with two abstentions) on question, "given the available efficacy and safety data, do the benefits of OCA 25 mg outweigh the risks in NASH patients with stage 2 or 3 fibrosis?" 15 of 16 voting-eligible advisors vote to "defer approval until clinical outcome data from trial 747-303 are submitted and reviewed, at which time the traditional approval pathway could be considered" PDUFA Target Action Date set for June 22, 2023 Company to host conference call on Monday, May 22, 2023, at 8:30 a.m. ET MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development

      5/19/23 6:45:00 PM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ICPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Akkaraju Srinivas returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)

      4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)

      11/13/23 2:51:46 PM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fundaro Paolo returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)

      4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)

      11/13/23 2:47:18 PM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Venezia Rocco returned $278,711 worth of shares to the company (14,669 units at $19.00), closing all direct ownership in the company (SEC Form 4)

      4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)

      11/13/23 2:49:33 PM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ICPT
    SEC Filings

    See more
    • SEC Form 15-12G filed by Intercept Pharmaceuticals Inc.

      15-12G - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Filer)

      11/20/23 12:09:56 PM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Intercept Pharmaceuticals Inc.

      EFFECT - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Filer)

      11/15/23 12:15:07 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Intercept Pharmaceuticals Inc.

      EFFECT - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Filer)

      11/15/23 12:15:03 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ICPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Intercept Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Subject)

      10/10/23 11:07:16 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Intercept Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Subject)

      7/10/23 10:41:25 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Intercept Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Subject)

      2/14/23 4:01:07 PM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care